Get the Stockscreener App
11.07
2.12%
0.23
After Hours:
11.29
0.22
+1.99%
Solid Biosciences Inc stock is traded at $11.07, with a volume of 2.85M.
It is up +2.12% in the last 24 hours and up +65.22% over the past month.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
See More
Previous Close:
$10.84
Open:
$10.81
24h Volume:
2.85M
Relative Volume:
1.82
Market Cap:
$1.09B
Revenue:
$14.79M
Net Income/Loss:
$-191.78M
P/E Ratio:
-5.6871
EPS:
-1.9465
Net Cash Flow:
$-172.86M
1W Performance:
+16.90%
1M Performance:
+65.22%
6M Performance:
+101.64%
1Y Performance:
+120.08%
1-Day Range:
$10.70
$11.45
1-Week Range:
$9.38
$11.45
52-Week Range:
$3.79
$11.45
Solid Biosciences Inc Stock (SLDB) Company Profile
Name
Solid Biosciences Inc
Sector
Industry
Phone
617-337-4680
Address
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Compare SLDB vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
11.07 | 983.51M | 14.79M | -191.78M | -172.86M | -1.9465 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-20-26 | Initiated | Guggenheim | Buy |
| Dec-04-25 | Initiated | Needham | Buy |
| Jun-26-25 | Initiated | Citigroup | Buy |
| Jan-08-25 | Initiated | Truist | Buy |
| Dec-13-24 | Initiated | Wedbush | Outperform |
| Dec-10-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-15-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-24-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| May-31-24 | Resumed | Piper Sandler | Overweight |
| Mar-28-24 | Initiated | William Blair | Outperform |
| Mar-15-24 | Initiated | Citigroup | Buy |
| Mar-14-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-08-23 | Initiated | H.C. Wainwright | Buy |
| Jul-12-21 | Initiated | Piper Sandler | Neutral |
| May-27-21 | Initiated | Jefferies | Buy |
| Mar-16-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-09-21 | Initiated | Barclays | Overweight |
| Jan-08-21 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jul-28-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-07-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-19 | Initiated | Evercore ISI | Outperform |
| Aug-29-19 | Downgrade | Citigroup | Neutral → Sell |
| Aug-19-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Aug-16-19 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| May-14-19 | Downgrade | Credit Suisse | Neutral → Underperform |
| May-14-19 | Downgrade | Goldman | Neutral → Sell |
| Feb-08-19 | Upgrade | Citigroup | Sell → Neutral |
| Feb-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-06-18 | Initiated | Citigroup | Sell |
| Sep-06-18 | Initiated | Credit Suisse | Neutral |
View All
Solid Biosciences Inc Stock (SLDB) Latest News
Does Solid Biosciences' (SLDB) Russell Index Debut Hint at a Turning Point in Its Growth Story? - simplywall.st
Does Solid Biosciences' (SLDB) Russell Growth Index Debut Reveal a Shift in Its Investor Base? - Yahoo Finance
RA CAPITAL MANAGEMENT, L.P. Increases Stake in Solid Biosciences Inc. - GuruFocus
Solid Biosciences Inc.(NasdaqGS:SLDB) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Solid Biosciences Inc.(NasdaqGS: SLDB) added to Russell 2500 Growth Benchmark - marketscreener.com
Solid Biosciences Inc.(NasdaqGS: SLDB) added to Russell 2000 Growth Benchmark - marketscreener.com
Solid Biosciences Inc.(NasdaqGS: SLDB) added to Russell 3000E Growth Benchmark - marketscreener.com
Solid Biosciences Inc.(NasdaqGS: SLDB) added to Russell 3000 Growth Benchmark - marketscreener.com
Price to sales forward of Solid Biosciences Inc. – NASDAQ:SLDB - TradingView
Enterprise value to EBITDA forward of Solid Biosciences Inc. – NASDAQ:SLDB - TradingView
Price to book forward of Solid Biosciences Inc. – NASDAQ:SLDB - TradingView
Price to earnings forward of Solid Biosciences Inc. – NASDAQ:SLDB - TradingView
SLDB Forecast — Price Target — Prediction for 2027 - TradingView
Solid Biosciences Inc. Actuals & Estimates (NASDAQ:SLDB) - TradingView
Solid Biosciences Inc (SLDB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Form 13D/A SOLID BIOSCIENCES INC. For: 24 June By Investing.com - Investing.com Australia
RA Capital discloses large SLDB stake with 8.18M pre-funded warrants - Stock Titan
RA Capital (NASDAQ: SLDB) boosts Solid Biosciences holding to 11.9% ownership - Stock Titan
Solid Biosciences Inc (SLDB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Solid Biosciences Inc (SLDB) Institutional Confidence - TradingKey
Solid Biosciences Inc.(NasdaqGS: SLDB) added to S&P Biotechnology Select Industry Index - marketscreener.com
Solid Biosciences Jumps As H.C. Wainwright Lifts Price Target - timothysykes.com
SLDB Jumps As Analyst Hikes Price Target To $25 - timothysykes.com
SLDB Jumps As H.C. Wainwright Hikes Price Target To $25 - timothysykes.com
Selling US$823k Of Solid Biosciences Stock Rewarded Insiders - Moomoo
Is Solid Biosciences (NASDAQ:SLDB) In A Good Position To Invest In Growth? - Sahm
Solid Biosciences Inc (SLDB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Solid Biosciences Inc (SLDB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Solid Biosciences Inc (SLDB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Solid Biosciences Inc. targets platform partnerships at BIO2026 in San Diego - Traders Union
Solid Biosciences Inc (SLDB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Solid Biosciences Inc (SLDB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Solid Biosciences Inc (SLDB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Solid Biosciences grants 77,500 options to director | SLDB Insider Trading - Stock Titan
Director at Solid Biosciences (NASDAQ: SLDB) granted 77,500 options - Stock Titan
Solid Biosciences (SLDB) director awarded 77,500 stock options at $6.61 strike - Stock Titan
Solid Biosciences (SLDB) director awarded 77,500 options via Perceptive Advisors - Stock Titan
Director at Solid Biosciences (SLDB) granted 77,500 stock options at $6.61 - Stock Titan
Solid Biosciences (SLDB) director receives 77,500 stock options at $6.61 exercise price - Stock Titan
Director at Solid Biosciences (NASDAQ: SLDB) receives 77,500 stock options grant - Stock Titan
Solid Biosciences (SLDB) grants director 77,500 stock options at $6.61 - Stock Titan
Solid Biosciences director granted 77,500 options | SLDB Insider Trading - Stock Titan
Solid Biosciences Shareholders Approve Directors and Share Increase - TipRanks
Solid Biosciences (NASDAQ: SLDB) shareholders approve doubling authorized stock - Stock Titan
Solid Biosciences Inc. targets industry collaboration ahead of BIO2026 to accelerate genetic medicine - Traders Union
Should I Buy SLDB (Solid Biosciences Inc.) | AI Analysis, Technical & News Insights - Kavout
SLDB: Gene therapy programs show robust efficacy, safety, and regulatory momentum for key indications - TradingView
Solid Biosciences Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Solid Biosciences (SLDB) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Analysts Offer Insights on Healthcare Companies: Vera Therapeutics (VERA) and Solid Biosciences (SLDB) - The Globe and Mail
SLDB (NASDAQ: SLDB) supplement lists updated selling stockholders and holdings - Stock Titan
Solid Biosciences Inc Stock (SLDB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):